Standard BioTools' Q3 Loss Widens Amid Revenue Dip, Soaring Restructuring Costs

TL;DR

**LAB is bleeding cash and revenue, and restructuring costs are skyrocketing – steer clear until they show a path to profitability.**

AI Summary

STANDARD BIOTOOLS INC. (LAB) reported a net loss of $34.687 million for the three months ended September 30, 2025, an increase from a net loss of $26.938 million in the same period of 2024. Total revenue decreased by 11.47% to $19.552 million in Q3 2025 from $22.086 million in Q3 2024, driven by declines in both product revenue (down 12.54% to $13.800 million) and services and other revenue (down 8.80% to $5.752 million). The company's loss from continuing operations widened to $32.938 million in Q3 2025 from $26.699 million in Q3 2024. Operating expenses saw a significant increase, primarily due to restructuring and related charges soaring to $9.428 million in Q3 2025 from $2.341 million in Q3 2024, a 302.73% jump. Selling, general and administrative expenses also rose to $26.595 million from $24.466 million. Cash and cash equivalents declined to $129.418 million as of September 30, 2025, from $166.728 million at December 31, 2024, reflecting net cash used in operating activities of $73.153 million for the nine months ended September 30, 2025.

Why It Matters

STANDARD BIOTOOLS INC.'s continued net losses and declining revenue signal persistent operational challenges, which could erode investor confidence and impact its ability to fund future research and development. The substantial increase in restructuring charges suggests ongoing strategic shifts and potential workforce reductions, directly affecting employees and potentially disrupting customer relationships. In a competitive life sciences market, LAB's struggle to achieve profitability and revenue growth puts it at a disadvantage against more stable rivals, making it harder to attract top talent and secure market share. Investors should be wary of the sustained cash burn and the lack of clear turnaround signs.

Risk Assessment

Risk Level: high — The company reported a net loss of $34.687 million for Q3 2025 and a net loss of $94.179 million for the nine months ended September 30, 2025. Revenue declined by 11.47% in Q3 2025 compared to Q3 2024, and cash and cash equivalents decreased by $37.31 million from December 31, 2024, to September 30, 2025, indicating significant cash burn and operational challenges.

Analyst Insight

Investors should exercise extreme caution and consider avoiding LAB stock given the widening losses, declining revenue, and substantial cash burn. Monitor future filings for concrete evidence of successful restructuring efforts and a clear path to profitability before considering any investment.

Financial Highlights

revenue

$19.552M

net Income

-$34.687M

eps

-$0.09

cash Position

$129.418M

revenue Growth

-11.47%

Revenue Breakdown

Key Numbers

• $19.552M — Total Revenue (Q3 2025) (Decreased from $22.086M in Q3 2024, an 11.47% decline.)
• $34.687M — Net Loss (Q3 2025) (Widened from $26.938M in Q3 2024.)
• $9.428M — Restructuring and Related Charges (Q3 2025) (Increased significantly from $2.341M in Q3 2024, a 302.73% jump.)
• $129.418M — Cash and Cash Equivalents (Sept 30, 2025) (Decreased from $166.728M at Dec 31, 2024.)
• $73.153M — Net Cash Used in Operating Activities (9 months ended Sept 30, 2025) (Indicates significant cash burn.)
• $0.09 — Net Loss Per Share (Q3 2025) (Increased from $0.07 in Q3 2024.)
• 384,565,414 — Common Stock Shares Outstanding (Nov 2, 2025) (Reflects total shares outstanding.)

Key Players & Entities

• STANDARD BIOTOOLS INC. (company) — registrant
• Illumina, Inc. (company) — transaction partner
• SEC (regulator) — filing oversight
• Nasdaq Global Select Market (market) — stock exchange
• South San Francisco, CA (location) — company headquarters
• Fluidigm (company) — trademark of Standard BioTools
• SomaLogic (company) — trademark of Standard BioTools
• Sengenics (company) — trademark of Standard BioTools

FAQ

Risk Factors

• Increased Net Loss and Cash Burn [high — financial]: The company reported a net loss of $34.687 million for Q3 2025, an increase from $26.938 million in Q3 2024. Net cash used in operating activities for the nine months ended September 30, 2025, was $73.153 million, contributing to a decline in cash and cash equivalents to $129.418 million.
• Significant Increase in Restructuring Charges [high — operational]: Restructuring and related charges surged by 302.73% to $9.428 million in Q3 2025 from $2.341 million in Q3 2024. This substantial increase indicates significant ongoing operational adjustments or challenges.
• Declining Revenue Trends [medium — market]: Total revenue decreased by 11.47% to $19.552 million in Q3 2025 from $22.086 million in Q3 2024. Both product revenue and services revenue experienced declines, suggesting potential market share loss or reduced demand.
• Rising SG&A Expenses [medium — operational]: Selling, general and administrative expenses increased to $26.595 million in Q3 2025 from $24.466 million in Q3 2024. While not as dramatic as restructuring charges, this rise in operating costs puts further pressure on profitability.

Industry Context

The biotechnology tools sector is highly competitive and capital-intensive, often characterized by long development cycles and significant R&D investment. Companies like STANDARD BIOTOOLS INC. face pressure from both established players and emerging innovators. Recent trends indicate a growing demand for advanced diagnostic and research tools, but also increasing scrutiny on profitability and operational efficiency.

Regulatory Implications

As a biotechnology company, STANDARD BIOTOOLS INC. is subject to stringent regulatory oversight from bodies like the FDA. Compliance with evolving regulations regarding product development, manufacturing, and marketing is critical. Any failure to adhere to these standards could result in significant fines, product recalls, or delays in market access, impacting financial performance.

What Investors Should Do

1. Monitor restructuring impact
2. Analyze revenue drivers
3. Assess cash burn rate

Key Dates

• 2025-09-30: End of Third Quarter 2025 — Reporting period for the latest 10-Q, showing increased net loss and decreased revenue.
• 2024-09-30: End of Third Quarter 2024 — Prior year comparable period, used to assess year-over-year performance changes.
• 2024-12-31: End of Fiscal Year 2024 — Balance sheet date for comparison of cash and cash equivalents.

Glossary

Continuing Operations

Refers to the ongoing business activities of a company that are expected to continue into the future, excluding discontinued operations. (The loss from continuing operations widened, indicating the core business is underperforming.)

Restructuring and Related Charges

Costs associated with significant reorganizations, such as layoffs, facility closures, or business unit divestitures. (A substantial increase in these charges highlights significant operational upheaval and associated costs.)

Cash and Cash Equivalents

Short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. (The decline in this position indicates a significant cash burn rate.)

Net Loss Per Share

The amount of net loss attributable to each outstanding share of common stock. (An increase in net loss per share signifies worsening profitability on a per-share basis.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, STANDARD BIOTOOLS INC. has experienced a significant downturn. Total revenue has fallen by 11.47%, indicating weakening demand or market position. The net loss has widened considerably, exacerbated by a more than 300% surge in restructuring and related charges, which also contributed to increased operating expenses. The company's cash position has also diminished, reflecting a substantial cash burn from operations.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share LAB The Nasdaq

Filing Documents

• lab-20250930.htm (10-Q) — 3150KB
• lab-ex31_1.htm (EX-31.1) — 18KB
• lab-ex31_2.htm (EX-31.2) — 19KB
• lab-ex32_1.htm (EX-32.1) — 10KB
• lab-ex32_2.htm (EX-32.2) — 10KB
• img188222183_0.jpg (GRAPHIC) — 178KB
• 0001193125-25-264695.txt ( ) — 12236KB
• lab-20250930.xsd (EX-101.SCH) — 1453KB
• lab-20250930_htm.xml (XML) — 2270KB

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 1 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 2 Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Cash Flows for nine months ended September 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 31 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 32 Item 1A.

Risk Factors

Risk Factors 32 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32 Item 3. Defaults Upon Senior Securities 32 Item 4. Mine Safety Disclosures 32 Item 5. Other Information 32 Item 6. Exhibits 33 EXHIBIT LIST 33

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

F inancial Statements

Item 1. F inancial Statements STANDARD BIOTOOLS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value) (Unaudited) September 30, December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 129,418 $ 166,728 Short-term investments 65,485 126,146 Accounts receivable, net 13,536 14,741 Inventory 25,418 20,744 Prepaid expenses and other current assets 7,906 4,561 Current assets held for sale 230,676 42,963 Total current assets 472,439 375,883 Property and equipment, net 20,738 22,775 Operating lease right-of-use asset, net 23,453 26,567 Other non-current assets 3,521 3,688 Long-term investments 19,485 — Non-current assets held for sale — 183,432 Total assets $ 539,636 $ 612,345 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 6,619 $ 5,049 Accrued liabilities 30,810 21,435 Operating lease liabilities, current 5,113 4,806 Deferred revenue, current 40,111 10,274 Deferred grant income, current 3,098 3,527 Current liabilities held for sale 22,214 20,804 Total current liabilities 107,965 65,895 Convertible notes, non-current 299 299 Deferred tax liability 1,139 1,081 Operating lease liabilities, non-current 21,977 25,590 Deferred revenue, non-current 2,366 32,674 Deferred grant income, non-current 5,031 7,243 Other non-current liabilities 1,200 1,062 Non-current liabilities held for sale — 6,779 Total liabilities 139,977 140,623 Commitments and contingencies (Note 6) Stockholders' equity: Preferred stock: $ 0.001 par value, 10,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common stock: $ 0.001 par value, 600,000 shares authorized at September 30, 2025 and December 31, 2024; 402,194 and 396,110 shares

View Full Filing

View this 10-Q filing on SEC EDGAR